SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is experiencing significant volatility following a post-earnings sell-off driven by weaker-than-anticipated second-quarter guidance and the announcement that co-founder Reed Hastings will exit the board. While the community is debating the stock's long-term strength versus short-term technical weakness, many investors are actively discussing whether this double-digit pullback represents a prime dip-buying opportunity or a signal to stay cautious amid concerns over subscriber growth and content spending.

Operates as a holding company with interest in providing social shopping platform solutions

WeShop Holdings Ltd - Ordinary Shares - Class A

WeShop Holdings Limited

WeShop Holdings Limited is currently trending as a high-volatility, low-float play that has ignited intense debate regarding a potential short squeeze. While bullish traders are actively targeting aggressive price levels, many in the community are warning of a classic pump-and-dump scheme characterized by frequent trading halts and erratic price swings.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is experiencing extreme volatility following the surprise appointment of industrial veteran Silvio Napoli as CEO and a significant $1.05 billion capital infusion, including an expanded robotaxi partnership with Uber. Despite these strategic updates, the stock is facing heavy downward pressure as investors weigh the dilution from new share offerings and persistent delivery and recall concerns against the company's long-term liquidity and technological ambitions.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is experiencing high volatility as investors react to news that a federal executive order regarding the use of ibogaine for PTSD treatment is expected to be signed. While some members of the community are betting on a massive short squeeze due to the company's tight float and the potential for a regulatory catalyst, others are expressing significant caution, citing the stock's history of reverse splits and unpredictable price swings.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is generating intense community buzz as traders track a potential breakout past the 10-cent psychological barrier while anticipating a broader meme coin rally. Enthusiasts are actively debating the currency's transactional utility and long-term potential, with many pointing to upcoming market events and historical cycles as catalysts for the next major movement.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Kennedy Space Center, FL.

Starfighters Space Inc

Starfighters Space is facing significant volatility as investors debate the impact of the CEO's sudden resignation and a pending annual report filing. The stock remains a focal point for day traders and community speculation regarding potential industry contracts and its correlation with broader aerospace sector movements.

Based is a financial superapp built on Hyperliquid that lets users trade crypto, equities, and commodities from a single interface, fund accounts directly from bank accounts or credit cards, and spend balances at over 100 million merchants worldwide using a Visa Platinum card that converts at the point of sale with no separate off-ramp required. The platform operates across web, iOS, Android, and desktop with one account, and includes features like curated Launchpools for early project access and AI-native wallets for autonomous trading and risk monitoring.

Based Token

The community is actively discussing the Based crypto super app and its potential for ecosystem-wide integration, balancing excitement over its ambitious feature roadmap against concerns regarding price volatility and high-leverage trading. Enthusiasts are highlighting the projects utility, including cross-chain interoperability and crypto-linked debit card offerings, while many participants closely watch volume patterns to gauge whether the token will sustain its recent momentum.

TOSHI

TOSHI is trending as investors speculate on a broader meme coin season and potential breakout, with community members closely watching volume patterns and social media rumors for signs of a reversal. Discussions remain highly polarized between long-term holders promoting the project as a core asset on the Base network and skeptics calling for caution amid volatile price movements.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is capturing significant investor attention as the stock undergoes a powerful rally, fueled by optimism surrounding its foundry expansion and strategic partnerships within the AI infrastructure sector. Community discourse is heavily focused on the stock's strong technical momentum, with traders debating whether this surge represents a sustainable breakout or a speculative bubble ahead of upcoming earnings.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is experiencing heavy volatility as investors weigh the potential of its new 800V-to-6V power delivery board for AI data centers against concerns over institutional selling and high short interest. While the community remains divided between long-term bulls betting on its strategic partnerships with AI infrastructure providers and skeptics fixated on the company's lack of consistent profitability and dilution risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tonix Pharmaceuticals Stock Hits New 52-Week Low: What's Driving The Action?

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading lower Monday morning, hitting a fresh 52-week low as investors weigh a new SEC filing alongside a biotech pipeline update from...

Tonix Pharmaceuticals (NASDAQ:TNXP) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen lowered shares of Tonix Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday...

<ul class="summary-bullets"><li>Tonix is now evaluating its Tonmya drug for the treatment of major depressive disorder and acute stress disorder/acute stress reaction.&nbsp;</li><li>The company also expects to initiate a U.S. field study in 2027 for its experimental drug TNX-4800 for seasonal prevention of Lyme disease.</li><li>According to data from Koyfin, both analysts covering TNXP rate it a ‘Buy’.</li></ul>Shares of Tonix Pharmaceuticals (TNXP) fell for the fourth consecutive day on Friday but stayed on the radar of retail investors on Stocktwits who gauged the company’s drug pipeline.Retail chatter around the stock rose 92% over the past 24 hours. Overall, retail sentiment around the stock fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A user said that the company should cut spending and focus resources on expanding the indication for the company’s FDA-approved drug Tonmya.<stembedurl>https://www.stocktwits.com/ByBi/message/648804308</stembedurl>Another user voiced optimism for the company’s Tonmya drug but noted that the stock is “super diluted.”<stembedurl>https://www.stocktwits.com/BlakeCanyon50/message/648764035</stembedurl>Yet another user voiced optimism for good news while adding that they think it is “very close.”<stembedurl>https://www.stocktwits.com/pickles14/message/648794046</stembedurl><h2 class="st-heading-2">Drug Approvals</h2>The U.S. Food and Drug Administration approved Tonix’s Tonmya for the management of fibromyalgia in adults in August. The non-opioid drug launched in November and through Feb. 27, more than 1,500 healthcare providers prescribed it to patients. About 2,500 patients have initiated treatment with Tonmya, the company said earlier this month.The company is now evaluating the potential of the drug in treating major depressive disorder and acute stress disorder/acute stress reaction.<h2 class="st-heading-2">Other Pipeline Updates</h2>Tonix expects to initiate a U.S. field study in 2027 for its experimental drug TNX-4800 for seasonal prevention of Lyme disease. There are no FDA-approved vaccines or prophylactics for the disease now.Other candidates in its pipeline include TNX-2900 for the treatment of Prader-Willi syndrome, TNX-1500 for the prevention of kidney transplant rejection, and TNX-1900 for the treatment of migraines.According to data from Koyfin, both analysts covering TNXP rate it a ‘Buy’. The 12-month average price target on the stock is $54.33, representing a potential upside of about 322%.<a href="https://stocktwits.com/symbol/TNXP">TNXP stock</a> has dropped 52% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/alt-stock-nearly-halved-in-past-year-but-wall-street-sees-almost-500-percent-upside/cZ3HgAcRImK">ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Tonix Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff

On Stocktwits, retail chatter around the stock rose 92% over the past 24 hours as users contemplated on the company’s approved drugs and investigational therapy candidates. 

Equity

Q1 Earnings Forecast for TNXP Issued By Zacks Research

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Equities researchers at Zacks Research issued their Q1 2026 earnings per share estimates for shares of Tonix Pharmaceuticals in a...

FY2028 Earnings Forecast for TNXP Issued By Zacks Research

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Equities research analysts at Zacks Research issued their FY2028 earnings estimates for Tonix Pharmaceuticals in a note issued to...

Seth Lederman Purchases 15,000 Shares of Tonix Pharmaceuticals (NASDAQ:TNXP) Stock

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) CEO Seth Lederman acquired 15,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 18th. The stock was acquired at an average price of $14.89 per share, for a total transaction of $223,350.00. Following...

Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Seth Lederman Acquires 15,000 Shares

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) CEO Seth Lederman acquired 15,000 shares of Tonix Pharmaceuticals stock in a transaction dated Wednesday, March 18th. The shares were purchased at an average price of $14.89 per share, with a total value of $223,350.00. Following...

Noble Financial Has Optimistic Outlook of TNXP Q1 Earnings

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Stock analysts at Noble Financial upped their Q1 2026 EPS estimates for shares of Tonix Pharmaceuticals in a research note issued on...

<ul class="summary-bullets"><li>CEO Seth Lederman said early trends show favorable prescriber uptake and repeat utilization.</li><li>Investors are also watching TNX-4800, with the company planning FDA talks on Phase 2/3 development and potential studies beginning in 2027-2028.</li><li>Tonix posted a net loss of $46.9 million in Q4, compared with a net loss of $22.1 million a year ago.</li></ul>Shares of Tonix Pharmaceuticals (TNXP) rose over 1% in premarket trading on Friday as investors cheered early prescription traction for its fibromyalgia drug Tonmya and growing interest in its Lyme disease prevention program, despite a wider quarterly loss.<a href="https://stocktwits.com/symbol/TNXP">TNXP stock</a> is headed for its seventh straight week of losses and has declined 0.3% so far this week.<h2 class="st-heading-2">Tonmya Launch Gains Early Prescriber Traction</h2>Tonix said Tonmya, approved by the U.S. Food and Drug Administration (FDA) in August 2025 for fibromyalgia in adults, is showing early adoption after its Nov.17, 2025, commercial launch. The therapy is the first new prescription medicine approved for fibromyalgia in more than 15 years.Through Feb.27, more than 1,500 healthcare providers had prescribed Tonmya, about 2,500 patients had initiated treatment and cumulative prescriptions reached nearly 4,200, including bridge prescriptions provided through the company’s specialty pharmacy channel.“Early prescription trends reflect favorable prescriber uptake and repeat utilization consistent with our internal launch expectations,” CEO Seth Lederman said in a statement. Tonix has established distribution through wholesalers, specialty pharmacies, and patient support programs, including copay assistance and prior authorization services.Speaking at the Life Sciences Virtual Investor Forum on Wednesday, Lederman said early anecdotal feedback suggests patients are reporting positive results and that prescribing is occurring across multiple specialties, including rheumatology, primary care, pain management and neurology.<h2 class="st-heading-2">Lyme Disease Prevention Drug In Focus</h2>Investors have also been paying attention to TNX-4800, a long-acting monoclonal antibody for the seasonal prevention of Lyme disease, an area with no FDA-approved vaccines or prophylactic treatments currently available.Tonix plans to meet with the FDA this year to discuss Phase 2/3 development options, including a field study and a controlled human infection model study. The company expects investigational products to be available in early 2027, with a U.S. field study potentially beginning in 2027 and a human challenge study planned for 2028.<h2 class="st-heading-2">TNXP Q4 Review</h2>Tonix reported fourth-quarter (Q4) revenue of about $534 million, significantly up from $2.6 million a year earlier. However, the company posted a net loss of $46.9 million, or $3.98 per share, compared with a net loss of $22.1 million, or $9.77 per share, in the same period a year ago.Tonix ended 2025 with $207.6 million in cash and cash equivalents, which will fund operations into the first quarter of 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for TNXP was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/tnxp_ss_png_63ee8c6e92.webp" alt="tnxp ss.png" width="969" height="141"><figcaption>TNXP sentiment and message volume as of March 13 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/curiousturtle2000/message/647416946">called</a> Tonix’s latest&nbsp;earnings report “very encouraging.”<stembedurl>https://stocktwits.com/curiousturtle2000/message/647416946</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/StockJayC/message/647411678">said</a>, “$20m-$25m cash burn = 2 years continuing at the current burn with no change to operations or factoring revenue increases,” adding that they expect the stock to rise over $60 by June.&nbsp;<stembedurl>https://stocktwits.com/StockJayC/message/647411678</stembedurl>TNXP stock has declined 14% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

TNXP Stock Rises Premarket: Investors Cheer Early Traction For Fibromyalgia Drug Despite Weak Q4 Print

Tonmya launch gained early uptake, with over 1,500 healthcare providers prescribing the drug until Feb.27.

Tonix Pharmaceuticals (NASDAQ:TNXP) Releases Earnings Results, Misses Estimates By $0.99 EPS

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) released its earnings results on Thursday. The company reported ($4.15) EPS for the quarter, missing the consensus estimate of ($3.16) by...

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

TNXP
Tonix Pharmaceuticals Holding Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TNXP News

TNXPTonix Pharmaceuticals Holding Corp